Treatment of recurrent epithelial ovarian cancer

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 421-426

  Pisano, Carmela ^a   Bruni, Giovanni S ^a   Facchini, Gaetano ^a   Marchetti, Claudia ^a   Pignata, Sandro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy; Ovarian cancer

Indexed keywords

AZB 2281; BEVACIZUMAB; CARBOPLATIN; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PLATINUM; TOPOTECAN; TRABECTEDIN; UNCLASSIFIED DRUG;

ALOPECIA; ARTHRALGIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HUMAN; INTESTINE PERFORATION; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROPATHY; NEUROTOXICITY; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 77949447507     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Bristow RE. Survival effect of maximal cytoreductive surgery for advance ovarian cancer in the platinum era: a metanalysis. J Clin Oncol. 2002;20:1248-1259.
2. du Bois A, Quinn M, Thigpen T, et al; for the Gynecologic Cancer Intergroup; AGO-OVAR; ANZGOG; EORTC; GEICO; GINECO; GOG; JGOG; MRC/NCRI; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG; IGCS; Organizational team of the two prior International OCCC. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16(Suppl 8):viii7-viii12.
3. Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol. 1999;93:21-24.
4. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol. 1991;9:1801-1805.
5. Parmar MK, Ledermann JA, Colombo N, et al. ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinumbased chemotherapy in women with relapsed ovarian cancer: the ICON4/AGOOVAR- 2.2 trial. Lancet. 2003;361:2099-2106.
6. Pfisterer J, Vergote I, Du Bois A, Eisenhauer E; AGO-OVAR, NCIC CTG, EORTC GCG. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer. 2005;15(Suppl 1):36-41.
7. Tummala MK, McGuire WP. Recurrent ovarian cancer. Clin Adv Hematol Oncol. 2005;3:723-736.
8. Vermorken JB, Harper PG, Buyse M. The role of anthracyclines in epithelial ovarian cancer. Ann Oncol. 1999;10(Suppl 1):43-50.
9. Lück HJ, Du Bois A, Weber B, et al; AGO-GINECO Intergroup. The integration of anthracyclines in the treatment of advanced ovarian cancer. Int J Gynecol Cancer. 2001;11(Suppl 1):34-38.
10. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16:405-410.
11. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1995;15:2183-2193.
12. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322.
13. O'Byrne KJ, Bliss P, Graham JD, et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naïve relapsed ovarian cancer [abstract 808]. Proc Am Soc Clin Oncol. 2002;21:203a.
14. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (29,29 difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530-1533.
15. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2007;25:5165-5171.
16. Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer. 2005;15(5):785-792.
17. Friedlander M, Hancock KC, Benigno B, et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study. J Clin Oncol. 2007;25(suppl):289s.
18. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol. 1995;13:1777-1785.
19. Vaage J, Barbera-Guillem E, Abra R, et al. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer. 1994;73:1478-1484.
20. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26(6):890-896.
21. Sehouli J, Stengel D, Oskay-Oezcelik G, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2008;26(19):3176-3182.
22. Tambaro R, Greggi S, Iaffaioli RV, et al. An escalating dose finding study of liposomal doxorubicin and or the treatment of refractory or resistant epithelial ovarian cancer. Ann Oncol. 2003;14:1406-1411.
23. D'Agostino G, Ferrandina G, Ludovisi M, et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer. 2003;89:1180-1184.
24. Monk BJ, Herzog T, Kaye S, et al. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). (LBA1) Ann Oncol. 2008;19(Supplement 8):viii1-viii4.
25. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101(3):436-440.
26. Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin. Cancer Res. 2005;11:5539-5548
27. Fong PC, Boss DS, Carden CP, et al. AZD281 (KU-0059436) A PARP (poly ADP-Ribose-polymerase) inhibitor with single-agent anticancer activity in patient with BRCA deficient ovarian cancer: results from a phase 1 study [abstract]. J Clin Oncol. 2008;26:5510.
28. Benedetti Panici P, De Vivo A, Bellati F, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol. 2007;14(3):1136-1142.
29. Harter P, du Bois A, Hahmann M, et al; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee; AGO Ovarian Cancer Study Group. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702- 1710.
30. Pignata S, De Placido S, Biamonte R, et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer. 2006;6:5.
31. Ferrero JM, Weber B, Geay JF, et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol. 2007;18(2):263-268.
32. Åvall-Lundqvist E, Wimberger P, Gladieff L, et al. Pegylated liposomal doxorubicin (PLD)-carboplatin (C) (C-D) vs paclitaxel-carboplatin (C-P) in relapsing sensitive ovarian cancer (OC): A 500-patient interim safety analysis of the CALYPSO GCIG Intergroup phase III study [abstract]. J Clin Oncol 2008;26(suppl):5565.
33. Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist. 1999;4:87-94.
34. Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol. 2003;88(1):17-21.
35. Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol. 2004;94(1):67-73.
36. Katz EJ, Vick JS, Kling KM, et al. Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. Eur J Cancer. 1990;26:724-727.
37. Pignata S, Ferrandina G, Scarfone G, et al. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology. 2006;71(5-6):320-326.